Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year—Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS)

Figure 1

Noninferiority analysis for the SPECT-based residual ischemia at 12 months in the three treatment arms with CABG as a reference method (a) and assuming no single reference method (b). Point estimates and 90% confidence intervals for the differences in RI between treatment modalities are shown with solid vertical gridline indicating the null difference and interrupted vertical gridline indicating the noninferiority margin of 4.2 percentage points. (a) Respective values are for noninferiority of MV-PCI vs CABG and HCR vs. CABG. To adjust for two comparisons with CABG as the reference values were considered statistically significant when <0.025. (b) values are for pairwise noninferiority tests with 95% one-sided confidence intervals. Overall for noninferiority is 0.046.

(a)

(b)